Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer

BACKGROUND: Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Riche, Kneebone, A., Eade, T., Hsiao, E., Emmett, L., Brown, Christopher, Hunter, J., Hruby, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394924/
https://www.ncbi.nlm.nih.gov/pubmed/37528487
http://dx.doi.org/10.1186/s13014-023-02302-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394924/
https://www.ncbi.nlm.nih.gov/pubmed/37528487
http://dx.doi.org/10.1186/s13014-023-02302-8

Ejemplares similares